



# Lilly Cares® Foundation 2024 State-Level Results

Diabetes Medications		
BAQSIMI® (glucagon) nasal powder; Basaglar® (insulin glargine injection); Humalog® (insulin lispro injection); Humulin® (human insulin); Lyumjev® (insulin lispro-aabc) injection; Trulicity® (dulaglutide) injection		
	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$300,000	36
AL	\$25,300,000	3106
AR	\$8,700,000	866
AZ	\$14,200,000	1382
CA	\$29,900,000	3014
CO	\$8,600,000	820
CT	\$4,300,000	462
DC	\$210,000	25
DE	\$3,400,000	344
FL	\$55,600,000	6093
GA	\$41,600,000	5049
HI	\$610,000	63
IA	\$9,900,000	971
ID	\$8,200,000	819
IL	\$30,600,000	3131
IN	\$53,900,000	5419
KS	\$16,400,000	1822
KY	\$20,000,000	2124
LA	\$18,700,000	1839
MA	\$13,300,000	1226
MD	\$15,900,000	1713
ME	\$7,000,000	727
MI	\$60,500,000	5458
MN	\$19,300,000	1873
MO	\$29,500,000	3008
MS	\$11,400,000	1203
MT	\$4,000,000	381
NC	\$67,000,000	7424
ND	\$2,000,000	197
NE	\$12,100,000	1218
NH	\$6,400,000	656
NJ	\$11,600,000	1382
NM	\$3,500,000	349
NV	\$7,700,000	725
NY	\$28,600,000	2807
OH	\$75,700,000	7448
OK	\$17,100,000	1842
OR	\$10,500,000	1012
PA	\$49,700,000	4936
PR	\$230,000	35
RI	\$5,100,000	496
SC	\$22,800,000	2315
SD	\$2,800,000	307
TN	\$42,600,000	4347
TX	\$117,500,000	12589
UT	\$13,300,000	1426
VA	\$40,000,000	4947
VI	\$20,000	2
VT	\$770,000	73
WA	\$14,000,000	1459
WI	\$33,600,000	3103
WV	\$10,300,000	992
WY	\$2,100,000	254
Basaglar®, Humalog®, Humulin®, Lyumjev® and Trulicity® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates. BAQSIMI® is a registered trademark of its owner.		



# Lilly Cares® Foundation 2024 State-Level Results

Neuroscience Medications [Mental Health, Migraine, Alzheimer's]		
Cymbalta® (duloxetine delayed-release capsules); Emgality® (galcanezumab-gnlm) injection; Kisunla™ (donanemab-azbt) injection; Prozac® (fluoxetine); REYVOW® (lasmiditan); Strattera® (atomoxetine); Zyprexa® (olanzapine)		
	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$20,000	3
AL	\$3,900,000	755
AR	\$610,000	90
AZ	\$1,400,000	189
CA	\$2,000,000	250
CO	\$1,500,000	194
CT	\$390,000	54
DE	\$250,000	29
FL	\$7,200,000	1190
GA	\$5,700,000	1003
HI	\$30,000	3
IA	\$1,100,000	143
ID	\$490,000	77
IL	\$1,400,000	201
IN	\$2,900,000	449
KS	\$1,600,000	281
KY	\$1,900,000	294
LA	\$830,000	146
MA	\$500,000	70
MD	\$890,000	135
ME	\$400,000	67
MI	\$2,500,000	361
MN	\$1,200,000	165
MO	\$2,400,000	330
MS	\$1,300,000	224
MT	\$550,000	81
NC	\$6,400,000	1099
ND	\$200,000	30
NE	\$690,000	106
NH	\$720,000	94
NJ	\$910,000	121
NM	\$230,000	31
NV	\$450,000	51
NY	\$1,500,000	194
OH	\$2,300,000	355
OK	\$1,500,000	288
OR	\$640,000	92
PA	\$3,200,000	474
PR	\$40,000	5
RI	\$90,000	16
SC	\$1,800,000	279
SD	\$710,000	125
TN	\$2,900,000	454
TX	\$26,900,000	4937
UT	\$630,000	75
VA	\$5,200,000	861
VT	\$150,000	19
WA	\$1,200,000	160
WI	\$1,800,000	251
WV	\$790,000	137
WY	\$450,000	73
Cymbalta®, Emgality®, Prozac®, REYVOW®, and Strattera® are registered trademarks and Kisunla™ is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates. Zyprexa® is a registered trademark of its owner.		



# Lilly Cares® Foundation 2024 State-Level Results

Cancer Medications		
Alimta® (pemetrexed for injection); Cyramza® (ramucirumab) injection; Erbitux® (cetuximab) injection; Jaypirca® (pirtobrutinib); Retevmo® (selpercatinib); Verzenio® (abemaciclib)		
	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$1,300,000	12
AL	\$13,100,000	137
AR	\$10,800,000	118
AZ	\$31,600,000	296
CA	\$72,400,000	596
CO	\$24,700,000	220
CT	\$12,400,000	112
DC	\$800,000	9
DE	\$3,000,000	26
FL	\$109,100,000	997
GA	\$42,900,000	415
HI	\$1,600,000	15
IA	\$10,900,000	99
ID	\$6,700,000	55
IL	\$43,600,000	389
IN	\$23,900,000	212
KS	\$13,000,000	110
KY	\$11,100,000	105
LA	\$12,700,000	119
MA	\$18,200,000	140
MD	\$20,600,000	172
ME	\$6,000,000	54
MI	\$26,100,000	229
MN	\$22,900,000	181
MO	\$24,400,000	216
MS	\$13,200,000	126
MT	\$4,200,000	36
NC	\$44,300,000	403
ND	\$2,000,000	20
NE	\$7,900,000	66
NH	\$4,900,000	43
NJ	\$43,700,000	368
NM	\$4,700,000	46
NV	\$10,200,000	99
NY	\$48,000,000	419
OH	\$56,300,000	510
OK	\$12,600,000	114
OR	\$18,600,000	158
PA	\$52,800,000	436
PR	\$1,700,000	14
RI	\$3,700,000	34
SC	\$19,200,000	181
SD	\$2,200,000	25
TN	\$28,800,000	248
TX	\$156,800,000	1370
UT	\$7,400,000	68
VA	\$36,000,000	318
VI	\$190,000	1
VT	\$2,000,000	17
WA	\$30,100,000	262
WI	\$32,900,000	258
WV	\$7,400,000	74
WY	\$1,400,000	11
Alimta®, Cyramza®, Erbitux®, Jaypirca®, Retevmo® and Verzenio® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.		



# Lilly Cares® Foundation 2024 State-Level Results

Immune Disorder Medications		
Ebglyss™ (lebrikizumab-lbkz) injection; Olumiant® (baricitinib); Taltz® (ixekizumab) injection		
	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$1,100,000	18
AL	\$24,100,000	340
AR	\$33,200,000	475
AZ	\$18,200,000	281
CA	\$41,900,000	620
CO	\$12,700,000	182
CT	\$7,700,000	109
DC	\$100,000	1
DE	\$4,200,000	57
FL	\$87,600,000	1278
GA	\$44,000,000	628
HI	\$4,300,000	65
IA	\$7,300,000	103
ID	\$11,800,000	158
IL	\$31,100,000	450
IN	\$38,100,000	526
KS	\$13,300,000	187
KY	\$12,300,000	189
LA	\$21,900,000	307
MA	\$12,200,000	170
MD	\$8,600,000	124
ME	\$5,100,000	66
MI	\$36,200,000	531
MN	\$17,700,000	248
MO	\$28,800,000	413
MS	\$9,300,000	131
MT	\$2,600,000	40
NC	\$37,700,000	584
ND	\$3,500,000	50
NE	\$6,900,000	96
NH	\$4,900,000	66
NJ	\$24,800,000	366
NM	\$3,800,000	54
NV	\$5,500,000	87
NY	\$33,900,000	507
OH	\$44,300,000	627
OK	\$20,900,000	293
OR	\$10,800,000	159
PA	\$33,600,000	469
PR	\$2,300,000	41
RI	\$2,800,000	40
SC	\$19,000,000	287
SD	\$3,100,000	47
TN	\$37,300,000	559
TX	\$109,800,000	1659
UT	\$10,000,000	149
VA	\$22,500,000	325
VT	\$1,100,000	17
WA	\$20,100,000	285
WI	\$17,200,000	231
WV	\$6,400,000	94
WY	\$1,700,000	22
Olumiant® and Taltz® are registered trademarks and Ebglyss™ is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.		



# Lilly Cares® Foundation 2024 State-Level Results

Women's, Men's, and Children's Health Medications		
Cialis® (tadalafil); Evista® (raloxifene hydrochloride); Forteo® (teriparatide injection); Humatrope® (somatropin) for injection		
	Value of Medications based on Wholesale Acquisition Cost	Patients Served
AK	\$440,000	11
AL	\$6,700,000	280
AR	\$3,300,000	94
AZ	\$4,300,000	118
CA	\$21,200,000	565
CO	\$6,900,000	159
CT	\$1,800,000	48
DE	\$660,000	22
FL	\$27,400,000	1343
GA	\$8,400,000	302
HI	\$300,000	6
IA	\$3,700,000	93
ID	\$5,000,000	128
IL	\$8,700,000	240
IN	\$13,000,000	349
KS	\$1,800,000	67
KY	\$4,200,000	137
LA	\$4,900,000	148
MA	\$5,500,000	125
MD	\$2,500,000	71
ME	\$1,500,000	43
MI	\$6,100,000	185
MN	\$6,800,000	175
MO	\$12,200,000	312
MS	\$2,300,000	132
MT	\$2,000,000	54
NC	\$13,100,000	414
ND	\$2,000,000	42
NE	\$2,100,000	61
NH	\$1,400,000	38
NJ	\$8,500,000	214
NM	\$2,100,000	48
NV	\$1,300,000	45
NY	\$9,000,000	267
OH	\$16,300,000	432
OK	\$3,400,000	114
OR	\$2,700,000	77
PA	\$14,400,000	394
PR	\$360,000	9
RI	\$810,000	28
SC	\$7,500,000	218
SD	\$2,000,000	44
TN	\$6,600,000	190
TX	\$25,700,000	884
UT	\$3,400,000	81
VA	\$6,300,000	249
VT	\$340,000	10
WA	\$5,800,000	151
WI	\$10,800,000	263
WV	\$2,300,000	58
WY	\$360,000	10

Cialis®, Evista®, Forteo® and Humatrope® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

Lilly Cares Foundation, Inc., Lilly Corporate Center, Indianapolis, IN 46285; Dan Collins, [d.collins@lilly.com](mailto:d.collins@lilly.com)